(a)
| Characteristic (n (%), by column) | Total | HBV DNA negative | HBV DNA positive | CI95% or P value |
|---|---|---|---|---|
| Study population (n (%), by row) | 405 | 381 (94.1) | 24 (5.9) | 3.8–8.7% |
| Serological markers of infection□ | ||||
| No HBV markers | 183 (45.2) | 174 (95.1) | 9 (4.9) | 2.3–9.1% |
| Anti-HBs + anti-HBc | 88 (21.7) | 82 (93.2) | 6 (6.8) | 2.5–14.2% |
| Anti-HBc alone | 71 (17.5) | 63 (88.7) | 8 (11.3)∗,∆ | 5.0–21.0% |
| Anti-HBs alone | 63 (15.6) | 62 (98.4) | 1 (1.6) | 0.1–8.5% |
| Anti-HCV | 98 (24.2) | 95 (96.9) | 3 (3.1) | 0.6–8.7% |
| HIV viral load | ||||
| HIV RNA [log10 copies/mL, median (IQR)) | 1.8 (3.0) | 1.8 (3.0) | 2.8 (3.1) | 0.834 |
| HIV RNA (≤50 copies/mL) | 196 (47.9) | 186 (94.9) | 10 (5.1) | 0.775 |
| HAART regimen | ||||
| Naïve | 145 (35.8) | 138 (95.2) | 7 (4.8) | |
| HAART including lamivudine | 160 (39.5) | 149 (93.1) | 11 (6.9) | |
| HAART without lamivudine | 53 (13.1) | 51 (96.2) | 2 (3.8) | |
| HAART not specified | 47 (11.6) | 43 (91.5) | 4 (8.5) | |
| Months of treatment (median (IQR)) | 55.2 (53.9) | 54.9 (55.1) | 58.1 (31.2) | 0.954 |
| Immunological parameters (n = 348) | ||||
| CD4 + cell counts (median (IQR)) | 390 (386) | 388 (382) | 419 (368) | 0.758 |
| ≤200 cells/mL | 79 (22.7) | 75 (94.9) | 4 (5.1) | |
| 201–499 cells/mL | 143 (41.1) | 136 (95.1) | 7 (4.9) | |
| ≥500 cells/mL | 126 (36.2) | 117 (92.9) | 9 (7.1) |